Source: Therapeutic Advances in Reproductive Health. Unidade: FMRP
Subjects: FERTILIDADE, HORMÔNIO LIBERADOR DE GONADOTROFINAS, NEOPLASIAS
ABNT
INGOLD, Caroline et al. Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review. Therapeutic Advances in Reproductive Health, v. 17, p. 1-11, 2023Tradução . . Disponível em: https://doi.org/10.1177/26334941231196545. Acesso em: 23 jan. 2026.APA
Ingold, C., Navarro, P. A. de A. S., Oliveira, R. de, Barbosa, C. P., & Bedoschi, G. (2023). Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review. Therapeutic Advances in Reproductive Health, 17, 1-11. doi:10.1177/26334941231196545NLM
Ingold C, Navarro PA de AS, Oliveira R de, Barbosa CP, Bedoschi G. Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review [Internet]. Therapeutic Advances in Reproductive Health. 2023 ; 17 1-11.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1177/26334941231196545Vancouver
Ingold C, Navarro PA de AS, Oliveira R de, Barbosa CP, Bedoschi G. Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review [Internet]. Therapeutic Advances in Reproductive Health. 2023 ; 17 1-11.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1177/26334941231196545
